Objectives: To identify suitable biomarkers during early stages of dengue to predict which 42 patients would develop severe forms of dengue before the warning signs appear.
Introduction from sample collection. Isolated peripheral blood cells (PBC) and saliva samples (after adding 30 145 mM NaOH) were stored at -80 °C until sample analysis. Ethical clearance for patient sample 146 collection was obtained from the ethics review committee of the Faculty of Medicine, University 147 of Kelaniya, Kelaniya, Sri Lanka (Reference number-P/119/07/2015).
148
Quantitative Real-time PCR: Gene specific human primers against the reference gene GAPDH 149 and iNOS were mined from previously published literature. 30 Total RNA was isolated from 150 peripheral blood cells using miRNeasy serum/plasma kit (Qiagen) with 700 μL QIAzol Lysis 151 buffer and 140 μL chloroform according to the manufacturer's instructions. cDNA was 152 synthesized using the miScript II RT Kit with Hiflex buffer from 12 µL extracted total RNA 153 according to product manual (Qiagen). Expression of mRNA was quantified using QuantiTect 154 SYBR Green PCR kit (Qiagen) according to product manual. Each reaction was carried out in 155 triplicates in 20 μL reaction volume using StepOne real-time PCR Thermal Cycler (Applied 156 Bio). The efficiency of amplification for iNOS was 106 % and GAPDH was 110 % based on the 157 standard curve analysis. No-template reactions and melting curve analysis was used to confirm 158 specificity of target amplification.
159
Quantification of plasma and salivary nitric oxide by Greiss reaction: Nitrite content in 160 plasma was measured according to a previously reported method using Griess reaction against a 161 standard series of NaNO2. 31 Plasma sample (60 µL) was deproteinized with 7.5 µL of 200 mM 162 ZnSO4 prior to assay for nitrites. 163 Salivary nitrite levels were detected by Griess colorimetric reaction as total nitrates and 164 nitrites as described by Miranda, Espey and Wink, (2000) with some modifications 32 . Saliva 165 sample (120 µL) was deproteinized with 15 µL of 200 mM ZnSO4 and mixture was centrifuged 166 for 3 min at 10,000 g at room temperature. 50 µL of supernatant, 50 µL of 2 % (w/v) 167 sulfanilamide in 5 % HCl (v/v) and 50 µL of 1 % (w/v) N-(1-Naphthyl) ethylenediamine 168 dihydrochloride in water were mixed to a final volume of 200 µL. Mixture was incubated at 169 room temperature for 20 mins and absorbance at 540 nm was measured using Multiskan Go 170 spectrophotometer (Thermo Scientific). Conversion of nitrates to nitrites by VCl3 followed by 171 colorimetric analysis for nitrites using Greiss reaction did not give higher nitrite reading 172 indicating that there are no nitrates in the samples.
174
Quantification of plasma and salivary oxLDL by ELISA: oxLDL content in plasma and saliva 175 was measured using human oxLDL ELISA kit (Elabscience) according to the manufactures 176 protocol with minor modifications. 5 µL of plasma was diluted 1:1000 in phosphate buffered saline 177 (PBS, pH 7) and 25 µL of diluted sample was assayed. 10 µL saliva was assayed in antibody pre 178 coated well of micro ELISA plate after dilution with 15 µL of PBS (pH 7). The oxLDL 179 concentration was calculated based on the concentration series of reference standards of oxLDL 180 provided with the assay kit as follows. Diluted saliva sample was removed from the well and 100 181 µL of biotinylated detection Ab was added into the well and incubated for 60 mins at 37 °C . Liquid 182 was aspirated and 100 µL of horse radish peroxidase conjugate was added into the well after 3 183 washes with wash buffer and incubated for 30 mins at 37 °C . Liquid was aspirated and 90 µL of 184 substrate reagent was added following 5 washes with wash buffer and incubated for 15 mins at 37 185 °C . 50 µL of stop solution was added and the absorbance was read at 450 nm by using Multiskan 186 Go spectrophotometer (Thermo Scientific).
187
Statistical Analysis: q-q plots and Shapiro-Wilk test were used to determine normality at a 95% 188 confidence interval. For the Shapiro-Wilk test P > 0.05 was determined as normal distribution.
189
The fold change of expression was calculated using the ΔΔCq method. A difference in 190 expression based on fold change of log base 2, less than 0.5 between DF and DHF cases was 191 considered as downregulation and above 1.5 was considered as upregulation. Statistical 192 significance for differentially expressed targets were determined based on the SEM of ΔCq using 193 independent t-test (SEM: Standard error of mean). Statistically significant differences among the 194 mean ± SD and mean ± SD of 5 th -95 th percentile was determined using independent t-test. were no statistically significant differences in mean, median, and 5 th -95 th percentile of mean 216 and median laboratory clinical parameters such as thrombocytopenia, leukopenia, hematocrit 217 count and AST and ALT levels in patients who later developed DHF compared with DF (Table   218 1, Table S1 ). Circulating AST and ALT levels were not significantly different between these two 219 groups throughout the course of infection (Table S2) . to decrease till day four from fever onset ( Fig. 1a , Table 2 ). Further analysis of iNOS expression 230 among the male patients (DF; n = 13 and DHF; n = 17) and female patients (DF; n = 6 and DHF; 231 n = 3) showed similar downregulation of iNOS expression ( Fig. 1b) . Expression analysis of 232 iNOS among the patients who showed signs of thrombocytopenia (< 100,000/mm 3 platelets) 233 during illness against those who did not develop thrombocytopenia, and a platelet count of < 234 60000/mm 3 as an indicator of severe dengue during illness against the patients of whom the 235 platelet count did not drop below 60000/mm 3 during the course of illness did not show 236 differential iNOS expression indicating that the expression of iNOS is not correlated with the 237 drop in platelet count (r = 0.05) ( Fig. 1c) . samples collected on day 2, day 3, day 4 and within 3 days from fever onset (Fig. 2a) . The data 278 are not normally distributed. Therefore, Mann-Whitney U test was used to determine significant 279 differences. However, this decrease of plasma NO in DHF patients within four days from fever 280 onset was observed among male patients (P < 0.05) but not in female patients (Fig. 2b) . This 281 may be due to fewer number of samples collected from females who later developed DHF.
282
Patients presenting with thrombocytopenia (20.6 ± 4.1 µM; n = 48) and patients presented with a 283 platelet count <60000/mm 3 showed a statistically significant (p < 0.05) decrease in plasma NO 284 levels (19.7 ± 3.5 µM; n = 34) compared to those with platelet count >100000/mm 3 (23.4 ± 7.1 285 µM; n = 11) and >60,000/mm 3 (23.4 ± 5.7 µM; n = 25) (Fig. 2c) . Since saliva is a non-invasive source of biological markers, we also quantified the 300 salivary NO levels in 38 patients with positive diagnosis for dengue using the Greiss reaction to 301 evaluate the potential as an early biomarker for severe dengue. Mann-Whitney U test was used to determine significant differences among the salivary NO 316 levels. Salivary NO concentration in groups did not show a statistically significant difference in 317 patient saliva collected within 4 days from fever onset (Fig. 3a) . The salivary NO levels in 318 dengue patients also did not correlate with the platelet count or the plasma NO concentration (r = 319 -0.02; r = 0.21) (Fig. 3b) . , 1996) . Therefore, plasma oxLDL levels were analyzed in 31 dengue positive patients 331 within four days from fever onset using ELISA. The clinical characteristics of the patients are 332 given in Table S5 . Mean plasma oxLDL concentration in DF (757.5 ± 343.9 ng/mL; n = 16) was 333 higher than that of DHF group (618.4 ± 224.2 ng/mL; n = 15). The data are normally distributed 334 (P > 0.05). Although the sample numbers in each group were low, the oxLDL levels in the DHF 335 group also showed a decrease in samples collected on day 2, day 3 and within 3 days from fever 336 onset with a statistically significant decrease in oxLDL levels in plasma collected within 3 days 337 from fever onset from patients who later developed DHF (P < 0.05) (Fig. 4a) . 338 oxLDL in sixteen saliva samples from patients with positive diagnosis for dengue within 339 four days from fever onset were analyzed using ELISA to evaluate whether the differences 340 observed in the plasma samples were detectable in saliva samples as well. Clinical characteristics 341 of the patients are given in Table S6 . Mean salivary oxLDL in DF patients (1.0 ± 0.4 ng/mL; n = 342 8) was significantly higher (p < 0.05) than that of DHF patients (0.6 ± 0.2 ng/mL; n=8) within 343 four days from fever onset suggesting that salivary oxLDL may serve as an early marker for 344 DHF (Fig. 4b) . The data are normally distributed. an early prognostic marker for severe dengue within 4 days from fever onset is 20 (nDF = 10; 379 nDHF = 10) indicating that the sample size used for the analysis is within the calculated limit. was not predictive of DHF after adjustment for number of days from fever onset (adjusted odds 394 ratio, 1.00; 95% CI 1.00-1.00, P < 0.05) with an area under the receiver operating curve of 0.62.
395
The sensitivity and specificity for the development of DHF were 0.73 and 0.50 respectively at 396 plasma oxLDL level of 729.7 ng/mL (P = 0.27). The calculated sample size to assess the 397 potential of plasma oxLDL to serve as a biomarker of severity of dengue infection within 4 days 398 from fever onset based on the normally distributed data (Shapiro-Wilk test P value > 0.05) is 392 399 and within 3 days from fever onset is 166.
400
Similarly, salivary oxLDL levels showed a significant decrease in the patients who later 401 developed DHF compared to the DF patients within 4 days of infection proving to be an 402 excellent non-invasive biological source for predictive markers for dengue. Salivary oxLDL 403 levels have been shown to correlate with the serum oxLDL levels 28 (De Giuseppe et al., 2015) .
404
Logistic regression analysis of salivary oxLDL levels within 4 days from fever onset was found 405 to be predictive of DHF with an area under the receiver operating curve of 0.91. The sensitivity 406 and specificity for the development of DHF were 0.88 and 0.75 respectively at salivary oxLDL 407 level of 0.8 ng/mL (P < 0.01). The calculated sample size to assess the potential of salivary 408 oxLDL to serve as an early marker of severe dengue is 18. However, oxLDL has also been 409 associated with cardiovascular risks 28 (De Giuseppe et al., 2015) . Therefore, oxLDL levels in a larger cohort of dengue patients during acute phase of infection may be necessary to validate the 411 role of oxLDL in saliva as a non-invasive early prognostic biomarker of DHF and evaluate the 412 effect of the confounding factors. Although saliva may serve as a non-invasive source for NO 413 levels, saliva was proven to be an unreliable biological source due to high standard deviation of 414 NO concentration that may be resulting from the influence of oral health and diet 35 (Mobarak).
415
Our study is limited by the relatively small sample sizes for 2, 3 and 4 days from fever onset and 416 relatively few samples from female patients to assess the potential of these markers to predict the 417 outcome within these parameters. Therefore, further analysis in a larger cohort is needed to 418 assess the full potential of these biomarkers to distinguish DF patients from those who progress 419 to DHF during the early stages of infection. Analysis of iNOS expression, plasma NO, plasma 420 oxLDL and saliva oxLDL in larger cohorts of dengue patients within each day from fever onset 421 during the acute phase and analysis of each of the above variables in a larger cohort of samples 422 from female patients is needed to evaluate the full potential of these markers to serve as early
